Checkmate to CHK1 in T-cell ALL?
Leonor M. Sarmento and João T. Barata DNA replication ensures accurate duplication of the original genetic information present in a cell in order for it to be properly transmitted to daughter cells. However, replication can be perturbed, for instance in rapidly dividing cancer cells, in a process referred to as replication stress (RS). Checkpoint kinase 1 (CHK1) is an essential component of the ATR-dependent DNA damageresponse pathway that protect cells from RS by preventing replication fork collapse and activating homologous DNA repair. The ATR-CHK1 pathway is triggered upon exposure of single-stranded DNA that arises with the stalling of replication forks [1] , and it is required to reset proper origin firing, and to promote fork stability and checkpoint activation, delaying mitosis until replication is completed and thereby avoiding mitotic catastrophe [2] . Whereas these functions point towards a tumor suppressor role for CHK1, mouse models modulating ATR-CHK1 expression and genetic evidence from human tumors suggest otherwise: Atr and Chk1 knock-out models do not display higher tumor frequency; Chk1 favors oncogeneinduced transformation in mice; CHK1 is frequently overexpressed in human cancers, while loss-of-function mutations are rare [2, 3] . Moreover, CHK1 affords protection against DNA damaging agents, a fact that prompted the use of CHK1 inhibitors as chemosensitizers [4] . Similarly, tumors whose oncogenic profile fuels RS were proposed to become addicted to ATR-CHK1 response [1, 2] . In our recent study published in Oncogene [5] , we hypothesized that T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematological cancer arising from T-cell precursor clonal expansion, could be one of such tumors and showed that CHK1 plays a key role in T-ALL cell maintenance.
T-ALL cells tend to be highly proliferative due to a myriad of genetic lesions that culminate in cyclin-dependent kinase hyperactivation, and deregulated progression of S-phase that may impact on DNA replication [5, 6] . We found that T-ALL cells overexpressed CHK1 mRNA and protein as compared to normal hematopoietic progenitors. This was accompanied by aberrantly high CHK1 kinase activity, likely triggered by high basal levels of RS [5] . Experimental inactivation of CHK1, by a CHK1 selective inhibitor (PF-00477736) or by gene silencing, demonstrated that CHK1 is essential to control the accumulation of RS and to prevent apoptosis of T-ALL cells that appear to enter mitosis without having concluded DNA replication. Furthermore, accumulation of DNA damage in the context of CHK1 loss induced the activation of the ATM-CHK2 DNA double-strand break (DSB) response pathway, likely due to DSB formation upon the collapse of stalled replication forks. T-ALL apoptosis upon CHK1 inactivation was in the first instance dependent on ATM and caspase-3, since ATM inhibition prevented caspase-3 cleavage and rescued T-ALL cell viability despite sustained elevated amounts of RS markers [5] .
Following the demonstration that T-ALL cells were eliminated using a CHK1 small molecule inhibitor as single agent, we showed that this effect was leukemiaspecific, since normal T-cell progenitors were not sensitive to the low doses of PF-00477736 that killed primary T-ALL patient cells. Moreover, the in vitro anti-leukemia effect of PF-00477736 was not prevented by microenvironment pro-survival factors, and the potential clinical value of CHK1 inhibition was further demonstrated by the fact that PF-00477736 limited the growth of xenografted T-ALL tumors [5] . Interestingly, our preliminary analyses indicated that T-ALL cells expressing higher CHK1 levels appeared more sensitive to CHK1 pharmacological inhibition, suggesting that CHK1 expression could be a suitable drug response marker in T-ALL patients. As clinical trials against ATR-CHK1 pathway may be envisaged, this issue warrants extended T-ALL patient analysis.
T-ALL constitutes only a fraction of all ALL cases, but it associates with high-risk. Therapeutic options with less detrimental side-effects and/or effective upon relapse are most desired. Our findings defining CHK1 as a 'subverted' tumor suppressor that stands in T-ALL as a major guardian of leukemia cell survival, thereby formally acting as an oncogene, reinforce a new way of viewing the mechanisms of cancer progression [2] and may set the ground for anti-leukemia breakthrough approaches. In this context, it is important to understand the mechanisms of CHK1 upregulation in T-ALL. We thoroughly documented CHK1 transcript overexpression in primary T-ALL [5] . However, how this occurs remains undetermined. Maybe transcription factors known to activate CHK1, such as E2F (downstream of G1/S-phase CDK activity) or MYC (downstream of NOTCH1), are involved in CHK1 overexpression in T-ALL. Or maybe as yet unidentified CHK1 regulatory elements are mutated or epigenetically altered. Curiously, in contrast to our findings, Chk1 mRNA downregulation was documented in a murine Editorial T-ALL model [7] . A more integrative view of the role of CHK1 in T-ALL is therefore required. We believe CHK1 downregulation may occur at T-ALL initiation, driving genomic instability secondary to an increase in RS. As the pro-proliferative oncogenic program establishes and RS rises, leukemic cells are naturally selected for their ability to upregulate CHK1 as a means to maintain RS levels compatible with cell viability.
